CClinicalTrials.gg
Enrolling by invitationNCT04989309Updated Jun 15, 2025

Left and Right Hemisphere Contributions to Speech Perception

An interventional study of Transcranial Magnetic Stimulation in Neural Bases of Speech Perception, sponsored by University of Connecticut. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by University of Connecticut · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Left and right temporal brain areas are thought to contribute to speech perception, but the division of labor between left and right hemisphere regions is still unclear. Here we use transcranial magnetic stimulation (TMS) to stimulate left and right temporal foci and a vertex control site to temporarily disrupt activation at the stimulation site, using a "virtual lesion" approach to test the effect of stimulation site on a series of speech perception tasks.

This portion of the project is basic research. However, since TMS is viewed as an intervention, studies involving TMS in this grant are considered clinical trials.

Read the detailed description

This study uses TMS to temporarily disrupt neural activity in the left and right temporal cortex and examine the effect of this disruption on speech perception tasks. Vertex stimulation is included as a control condition against which left and right superior temporal stimulation effects are compared. Adult participants first undergo structural MRI and a speech localizer using functional MRI to identify speech-sensitive voxels in the left and right temporal cortex. These regions are set by-participant as the foci for stimulation. Stimulation site is blocked, and typically distributed across sessions. 10 Hz pulse trains of 2.5 sec each are delivered to the stimulation site, with an auditory stimulus arriving either immediately after the last pulse (Exps 2 and 6) or, for longer sentence level stimuli (Exp 3), during the pulse train. Behavioral measures include accuracy and reaction times to rate phonetic stimuli (Exp 2), detect the presence of a probe word in the preceding sentence (Exp 3), or categorize stimuli by phonetic contrast and talker (Exp 6).

02

Conditions studied

  • Neural Bases of Speech Perception

Keywords

  • Speech perception
  • Left temporal lobe
  • Right temporal lobe
03

In context

Lead sponsor

University of Connecticut is the lead sponsor of 133 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Monolingual native speaker of English
  • No history of neurological impairments or disease
  • Free of speech and language disorders (per self-report, and confirmed by short language battery described by Fidler, Vance, \& Plante, 2011)
  • Pure-tone thresholds of 30 decibels or better in both ears (no worse than mild hearing loss), with no more than 15 dB between-ear difference.
  • Right-handed, as confirmed by Oldfield Handedness Inventory

Exclusion criteria

Exclusion Criteria:

  • Any condition where TMS would be contraindicated according to the most recent guidelines, including, but not limited to:

    • History of seizure or epilepsy
    • Metal in the skull
    • Use of legal or illicit drugs that can potentially reduce the threshold for seizure. As examples, we list some exclusionary drugs in each of the following categories. This is not an exhaustive list of the exclusionary drugs. We consult with faculty in the University of Connecticut College of Pharmacy to check for seizure risk with other drugs that participants report.

      • Antidepressants including Imipramine, amitriptyline, sertraline, venlafaxine, buproprion
      • Antipsychotics including Chlorpromazine, clozapine, haloperidol, aripiprazole
      • Antivirals including foscarnet, ganciclovir
      • Antiparasitics including chloroquine, mefloquine (antiparasitics)
      • Antibiotics including penicillin, ampicillin
      • Immunosuppressants including cyclosporin
      • Anticholinergenics
      • Antihistimines (including over-the-counter drugs like Claritin \& Benadryl)
      • Sympathomimetics (including Sudafed, Ritalin).
      • Illegal drugs such as methamphetamines, cocaine, MDMA, ketamine.
    • Diagnosis of a psychiatric disorder (per self-report)
    • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Experiment 2. Phonetic precision disrupted by TMS

    Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed "dog" to "cat" object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens.

    Device: Transcranial Magnetic Stimulation

  • Experimental
    Experiment 3. Phonetic ambiguity in continuous speech

    Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence ("BRASS?"). Dependent variables are accuracy and reaction time on this probe verification task.

    Device: Transcranial Magnetic Stimulation

  • Experimental
    Experiment 6: Disruption of talker-specific phonetic learning using TMS.

    Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in "coal") and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. "gain" vs. "cane"). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker.

    Device: Transcranial Magnetic Stimulation

Interventions

  • DeviceTranscranial Magnetic Stimulation

    TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.

06

What researchers measure

Primary outcomes

  1. Categorization accuracy

    Participants categorize items which vary along a perceptual continuum. Steepness of the categorization curve is extracted to estimate categorization accuracy.

    Time frame: Immediately following the stimulation pulses (within one second of the final pulse).

  2. Two-alternative forced choice accuracy

    Participants are given two options and asked to indicate which item they heard in the previous signal. Accuracy in making this decision is a primary outcome measure.

    Time frame: Immediately following the stimulation pulses (within one second of the final pulse).

  3. Two-alternative forced choice reaction time

    Participants are given two options and asked to indicate which item they heard in the previous signal. Reaction time to make this decision is a primary outcome measure.

    Time frame: Immediately following the stimulation pulses (within one second of the final pulse).

07

Study locations

1 site
  • University of Connecticut
    Storrs, Connecticut 06268, United States
08

References and documents

Publications

  • Kennedy-Higgins D, Devlin JT, Nuttall HE, Adank P. The Causal Role of Left and Right Superior Temporal Gyri in Speech Perception in Noise: A Transcranial Magnetic Stimulation Study. J Cogn Neurosci. 2020 Jun;32(6):1092-1103. doi: 10.1162/jocn_a_01521. Epub 2020 Jan 14. PubMed 31933438 ↗
  • Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. PubMed 33243615 ↗

Individual participant data

Plan to share: Yes — Results of these studies will be used for teaching, research publications, and presentation at scientific meetings. De-identified raw data of all types (behavioral, MRI) will be available upon request after publication. MRI data will be processed ("skull stripped") to remove any identifiable anatomy before archival. We will archive data locally using Brain Imaging Data Structure (BIDS) naming conventions to facilitate data sharing. We plan to pre-register behavioral studies on the Open Science Framework (or similar platforms), and in the interests of scientific transparency, we will post de-identified behavioral data and analysis code on Open Science Framework or GitHub.

Supporting information: Sap, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04989309
Lead sponsor
University of Connecticut
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
Responsible party
Emily Myers (Professor, University of Connecticut) — Principal investigator
First posted
Aug 4, 2021
Start date
Dec 19, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion